Clinical validation and commercialization of innovative immunostimulating Interstitial Laser Thermotherapy
Sector: Hospital • Location: Sweden
Source: EU Funding & Tenders Portal
The INTHER project will bring the groundbreaking immunostimulating Interstitial Laser Thermotherapy (imILTCLS) to the market and clinical practice. This minimally invasive therapy is designed to achieve local tumour destruction and stimulate specific antitumour immunity in a patient’s body. In recent years, anti-cancer therapies based on activation of the immune system have grown in significance a
- Status
- Closed
- Sector
- Hospital, Commercial
- Location
- Sweden
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Clinical validation and commercialization of innovative immunostimulating Interstitial Laser Thermotherapy
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The INTHER project will bring the groundbreaking immunostimulating Interstitial Laser Thermotherapy (imILTCLS) to the market and clinical practice. This minimally invasive therapy is designed to achieve local tumour destruction and stimulate specific antitumour immunity in a patient’s body. In recent years, anti-cancer therapies based on activation of the immune system have grown in significance and popularity. This approach is especially viable for patients who previously had very few treatment options. However, only approx. 20 % of all patients respond to drug-based immunotherapies of today. The key need of medical oncologists is to increase those response rates and thus decrease cancer-related suffering, increase life expectancy and survival rates for the patients. The project will meet those needs by delivering a novel device-based cancer immunotherapy method that destroys the tumour locally and induces long-lasting, vaccination-like, systemic immunity against the treated form of cancer. As the world’s first device-based laser immunotherapy, imILTCLS will curve its own market niche on the fast growing Cancer Immunotherapy Market and therefore have a significant disruptive effect on this market. The studies performed to date have confirmed the therapeutic capability of the new method. In the project, the method will be further validated for the two chosen solid tumour types: pancreatic cancer and breast cancer. This will enable CLS to shorten the time to full commercialisation, obtain the clinical acceptance and fully exploit the commercial potential of the new treatment method. The clinical uptake of imILTCLS in Europe will lead to reduction of costs associated with the treatment of solid tumours, especially surgeries, and reduction of costs related to the activation of immunotherapies. CLS’ strategy is based on intensive efforts towards validating imILTCLS and bringing it to the market. The project is a key step towards realizing this business strategy. |
Location
Country | Sweden |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital, Commercial |
Article published date | 2026-01-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Sweden
- Pfizer Genotropin Manufacturing, Strangnas
- Pronova Biopharma Pharmaceutical Production Facility
- GEA Niro Pharmaceutical Spray Drying Facility, Copenhagen
- Kemwell Pharmaceutical Manufacturing Facility
- GETINGE MEDICAL TECHNOLOGY RDI (RSFF)
- NEW KAROLINSKA SOLNA PPP
- Pre-A market expansion to SaaS and Clinical Seq
- PROJECT SMART COOL (IEU TI)
